Mar 07, 2022 / 07:15PM GMT
Andrew Cooper - Raymond James Financial Inc. - Analyst
Good afternoon. Thanks for joining us. I'm Andrew Cooper. I cover diagnostics at Raymond James. We're excited to have NeoGenomics here with us this afternoon; a long-time leader in the pure-play oncology diagnostics space. Over the last few years, it made some major moves in terms of some of the faster growing areas of oncology we're going to jump into, with some more proprietary offerings. So without further ado, I've got CFO, Bill Bonello; and Charlie Eidson here, who leads the IR effort.
Maybe to start us off, Bill, why don't -- if you don't mind -- you give us just, for some of the folks that are a little bit newer to the story, a bit of an overview who NeoGenomics is at the core, the markets you play in, and the landscape as you see it at a high level.
Bill Bonello - Neogenomics, Inc. - CFO
Sure. Thanks a lot, Andrew. So NeoGenomics, we are a cancer-testing laboratory. We're a comprehensive provider of cancer testing. So we have a broad menu of more than 600 tests. We have over 4,500 different
Neogenomics Inc at Raymond James Institutional Investors Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers